Enlivex Ltd. Ordinary Shares (ENLV) Stock Price
ENLVStock
$1.52−90.41%52W
Market Cap$26.58M
P/E0.02x
PEG Ratio—
Div yield—
Beta1.35
ENLV Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-102.26%
Price vs S&P 500 (4W)-35.64%
VGM Score53.92
P/E Ratio (Annual)0.02x
ENLV Earnings Surprise History
Q1 25-2.25est. -2.40
Q2 25-1.20est. -2.40
Q3 25-1.35est. -1.80
Q4 25-1.41est. -0.45
ENLV Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ENLVEnlivex Ltd. Ordinary Shares | A | — | F | $1.52 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About Enlivex Ltd. Ordinary Shares
Enlivex Ltd is a clinical-stage immunotherapy company developing Allocetra, a macrophage reprogramming therapy for osteoarthritis currently in late-stage clinical development. The company's platform leverages immune cell reprogramming technology to address degenerative joint disease.